• Market Trends Highlighted in Tear Film and Ocular Surface (TFOS) Conference in Montpellier Confirm Need for Redwood Pharmas Dry Eye Therapy

    Women make up two thirds of those suffering from Dry Eye Disease (DED). Presentations and scientific results shown at TFOS, which was held between Sep. 7-10 in Montpellier, demonstrated that sex should be considered as a biological parameter, as well as encouraged researchers to better understand the unique needs of women. By focusing on women’s […]

  • Japanese patent granted for IntelliGel platform

    The granting of a Japanese patent for the IntelliGel® platform opens a significant global market within ophthalmic medicines to Redwood Pharma. It is estimated that the total Japanese market in 2014 for prescription ophthalmic medicines was valued at USD 3.2 billion[1]. Redwood Pharma has now strengthened its commercial possiblities to exploit this market. Redwood Pharma […]

  • Redwood Pharma to present at French-Swedish Life Science Day 2016

    On October 20th, Redwood Pharma AB (publ.) will present at the French-Swedish Life Science Day organized by Business Sweden, the Swedish Embassy and strategic partners at the Swedish Embassy in Paris.  The conference will gather early stage and highly innovative medical technology and biotechnology companies from Sweden and France. European life science investors as well […]

  • Redwood Pharma to attend leading conference on ocular tear film science

    The 8th International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance will occur from September 7-10, 2016 in Montpellier, France. This Conference is sponsored by TFOS ( and is designed to assess the current knowledge and ‘state of the art’ research on the structure and function of the tear film […]

  • Redwood Pharma attending OIS-ASRS Conference in San Francisco

    Redwood Pharma attending OIS-ASRS Conference in San Francisco Redwood Pharma AB (publ) announces that it will be attending the Ophthalmology Innovation Summit-American Society for Retina Specialists (OIS-ASRS) in San Francisco, California, USA on August 8, 2016. The summit will focus on innovative treatments for back of the eye or retinal diseases. One of the more […]

  • Redwood Pharma to Present at BIO 2016 in San Francisco

    Redwood Pharma AB (publ) has been invited to the BIO 2016 conference to present Redwood Pharma’s drug candidate RP101 and drug delivery platform IntelliGel®. BIO 2016 is the world’s largest conference on biotech. The conference takes place in San Francisco, CA, USA between June 6 to 9. Over 15,000 participants will meet in San Francisco […]

  • Redwood Pharma raises SEK 6.6 million in private placement

    Stockholm, Sweden – Redwood Pharma AB has completed a SEK 6.6 million private placement to fund development of its lead product candidate RP101 for the treatment of chronic Dry Eye Disease. The active substance has been successfully tested in two human clinical Phase II studies and will now be tested in combination with IntelliGel®, the company’s […]

  • Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies

    Stockholm, Sweden – Redwood Pharma AB has entered into a licensing agreement with Broda Technologies Co., Ltd., operating in both the US and China, to use the company’s proprietary IntelliGel(R) supramolecular hydrogel technology in its lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies.  The Broda technology offers many unique competitive benefits.  At […]